Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances

被引:28
|
作者
Reilly, Christopher R. [1 ]
Shimamura, Akiko [2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA USA
[2] Dana Farber Boston Childrens Canc & Blood Disorder, Dept Pediat Hematol Oncol, Boston, MA USA
[3] Boston Childrens Hosp, 1 Blackfan Circle,Karp 8210, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
STEM-CELL TRANSPLANTATION; P53 PROTEIN OVEREXPRESSION; BONE-MARROW; SBDS GENE; CLONAL HEMATOPOIESIS; RIBOSOME BIOGENESIS; ISOCHROMOSOME; 7Q; EIF6; RELEASE; 60S SUBUNIT; MOUSE MODEL;
D O I
10.1182/blood.2022017739
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Shwachman-Diamond syndrome (SDS) is an inherited multisystem ribosomopathy characterized by exocrine pancreatic deficiency, bone marrow failure, and predisposition to myeloid malignancies. The pathobiology of SDS results from impaired ribosomal maturation due to the deficiency of SBDS and the inability to evict the antiassociation factor eIF6 from the 60S ribosomal sub-unit. Clinical outcomes for patients with SDS who develop myeloid malignancies are extremely poor because of high treatment-related toxicities and a high rate of refractory disease/relapse even after allogeneic hematopoietic stem cell transplant (HSCT). Registry data indicate that outcomes are improved for patients with SDS who undergo routine bone marrow surveillance and receive an HSCT before developing an overt malignancy. However, the optimal approach to hematologic surveillance and the timing of HSCT for patients with SDS is not clearly established. Recent studies have elucidated distinct patterns of somatic blood mutations in patients with SDS that either alleviate the ribosome defect via somatic rescue (heterozygous EIF6 inactivation) or disrupt cellular checkpoints, resulting in increased leukemogenic potential (heterozygous TP53 inactivation). Genomic analysis revealed that most myeloid malignancies in patients with SDS have biallelic loss-of-function TP53 mutations. Single-cell DNA sequencing of SDS bone marrow samples can detect premalignant biallelic TP53-mutated clones before clinical diagnosis, suggesting that molecular surveillance may enhance the detection of incipient myeloid malignancies when HSCT may be most effective. Here, we review the clinical, genetic, and biologic features of SDS. In addition, we present evidence supporting the hematologic surveillance for patients with SDS that incorporates clinical, pathologic, and molecular data to risk stratify patients and prioritize transplant evaluation for patients with SDS with high-risk features.
引用
收藏
页码:1513 / 1523
页数:11
相关论文
共 50 条
  • [1] Shwachman-Diamond syndrome: diagnosis, pathogenesis and prognosis
    Valli, Roberto
    Frattini, Annalisa
    Minelli, Antonella
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (10): : 753 - 767
  • [2] Shwachman-Diamond Syndrome: Diarrhea, no Longer Required?
    Andolina, Jeffrey R.
    Morrison, Colleen B.
    Thompson, Alexis A.
    Chaudhury, Sonali
    Mack, A. Kyle
    Proytcheva, Maria
    Corey, Seth J.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2013, 35 (06) : 486 - 489
  • [3] Pluripotent stem cell model of Shwachman-Diamond syndrome reveals apoptotic predisposition of hemoangiogenic progenitors
    Hamabata, Takayuki
    Umeda, Katsutsugu
    Kouzuki, Kagehiro
    Tanaka, Takayuki
    Daifu, Tomoo
    Nodomi, Seishiro
    Saida, Satoshi
    Kato, Itaru
    Baba, Shiro
    Hiramatsu, Hidefumi
    Osawa, Mitsujiro
    Niwa, Akira
    Saito, Megumu K.
    Kamikubo, Yasuhiko
    Adachi, Souichi
    Hashii, Yoshiko
    Shimada, Akira
    Watanabe, Hiroyoshi
    Osafune, Kenji
    Okita, Keisuke
    Nakahata, Tatsutoshi
    Watanabe, Kenichiro
    Takita, Junko
    Heike, Toshio
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [4] Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants
    Kawashima, Nozomu
    Oyarbide, Usua
    Cipolli, Marco
    Bezzerri, Valentino
    Corey, Seth J.
    HAEMATOLOGICA, 2023, 108 (10) : 2594 - 2605
  • [5] Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome
    Dror, Yigal
    Donadieu, Jean
    Koglmeier, Jutta
    Dodge, John
    Toiviainen-Salo, Sanna
    Makitie, Outi
    Kerr, Elizabeth
    Zeidler, Cornelia
    Shimamura, Akiko
    Shah, Neil
    Cipolli, Marco
    Kuijpers, Taco
    Durie, Peter
    Rommens, Johanna
    Siderius, Liesbeth
    Liu, Johnson M.
    ANNALS MEETING REPORTS, 2011, 1242 : 40 - 55
  • [6] Shwachman-Diamond Syndrome Presenting as Hypoglycemia
    Albrecht, Lindsey A.
    Gorges, Sandra W.
    Styne, Dennis M.
    Bremer, Andrew A.
    CLINICAL PEDIATRICS, 2009, 48 (02) : 212 - 214
  • [7] A clinical algorithm predicts hematological complications in Shwachman-Diamond syndrome?
    Liu, Johnson M.
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (04) : 373 - 375
  • [8] Shwachman-Diamond Syndrome: A Review of the Clinical Presentation,, Molecular Pathogenesis, Diagnosis, and Treatment
    Burroughs, Lauri
    Woolfrey, Ann
    Shimamura, Akiko
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (02) : 233 - +
  • [9] Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives
    Bezzerri, Valentino
    Cipolli, Marco
    MOLECULAR DIAGNOSIS & THERAPY, 2019, 23 (02) : 281 - 290
  • [10] Malignant myeloid transformation with isochromosome 7q in Shwachman-Diamond syndrome
    Dror, Y
    Squire, J
    Durie, P
    Freedman, MH
    LEUKEMIA, 1998, 12 (10) : 1591 - 1595